跳到正文
原文
Nature 健康护理主题·· 2026-10-03AI 评分17

对《玻璃体腔药物治疗的药理学原则及其临床实践意义:眼科医生入门》的评论:aflibercept 8 mg“眼内清除更慢”说法存疑

Comment on: ‘Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist’

AI 导读

针对 Ezzine 等关于玻璃体腔抗 VEGF 治疗药理学原则的综述,del Amo 等人在 Eye 发表的通讯指出,其中 aflibercept 8 mg 相较 2 mg“眼内清除更慢”的概念尚未获验证。作者提到,被引用的群体药代动力学(popPK)模型模拟称 aflibercept 8 mg 因清除更慢可将 VEGF 抑制延长 6 至 8.9 周,但该解读需谨慎对待。

正文
  • Correspondence
  • Published: 03 October 2026

Eye (2026) Cite this article

To the Editor:

We read with great interest the review by Ezzine et al. discussing the pharmacological principles of intravitreal anti-VEGF therapies [1]. While providing a useful overview, the pharmacokinetic interpretation warrants caution. In particular, the unverified concept of “slower ocular clearance” for aflibercept 8 mg versus 2 mg needs consideration. The authors highlight a population pharmacokinetic (popPK) model simulation claiming that aflibercept 8 mg prolongs VEGF suppression by 6 to 8.9 weeks due to a “slower ocular clearance” [2].

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Subscribe to this journal

Receive 18 print issues and online access

251,40 € per year

only 13,97 € per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

39,95 €

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Fig. 1: Simulated intravitreal concentration-time profiles of aflibercept.

Data availability

The simulation model, equations, and parameter datasets generated during the current study are available from the corresponding author upon reasonable request.

References

  1. Ezzine S, Gale R, Bailey C, Patel PJ, Sivaprasad S, Keshk Z, et al. Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist. Eye. 2026. https://doi.org/10.1038/s41433-026-04540-y.

  2. Kaiser PK, Turner KC, Bihorel S, Chiu J, Harnisch L, Chittenden J, et al. Population pharmacokinetic modeling and simulation of ocular clearance for aflibercept 8 mg and 2 mg and association with durability of effect [abstract]. Investig Ophthalmol Vis Sci. 2024;65:3154 https://doi.org/10.1167/iovs.65.7.3154.

    Article  Google Scholar 

  3. Birkett DJ. Pharmacokinetics made easy. 2nd ed. Sydney: McGraw-Hill Australia; 2010.

  4. Garcia-Quintanilla L, Luaces-Rodríguez A, Gil-Martínez M, Mondelo-García C, Maroñas O, Mangas-Sanjuán V, et al. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration. Pharmaceutics. 2019;11:365.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–32.

    Article  PubMed  Google Scholar 

Download references

Funding

The authors received no specific financial support or external funding for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland

    Eva M. del Amo

  2. Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain

    Víctor Mangas-Sanjuán

  3. FarmaCHUSLab Group & Pharmacy Department, Hospital Clínico Universitario de Santiago de Compostela (SERGAS), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain

    Anxo Fernández-Ferreiro

Authors

  1. Eva M. del Amo
  2. Víctor Mangas-Sanjuán
  3. Anxo Fernández-Ferreiro

Contributions

A.F.F., V.M.S. and E.M.dA. conceptualised the correspondence letter, wrote, reviewed, and approved the final manuscript.

Corresponding author

Correspondence to Anxo Fernández-Ferreiro.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

del Amo, E.M., Mangas-Sanjuán, V. & Fernández-Ferreiro, A. Comment on: ‘Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist’. Eye (2026). https://doi.org/10.1038/s41433-026-04922-2

Download citation

  • Received: 23 June 2026

  • Revised: 02 September 2026

  • Accepted: 15 September 2026

  • Published: 03 October 2026

  • Version of record: 03 October 2026

  • DOI: https://doi.org/10.1038/s41433-026-04922-2

来源:Nature 健康护理主题 · nature.com